Triheptanoin was also designated an orphan drug by the European Medicines Agency (EMA).Triheptanoin was approved for medical use in the United States in June 2020.The FDA approved triheptanoin based on evidence from three clinical trials (Trial 1/NCT018863, Trial 2/NCT022141 and Trial 3/NCT01379625). The trials enrolled children and adults with LC-FAOD. Trials 1 and 2 were conducted at 11 sites in the United States and the United Kingdom, and Trial 3 was conducted at two sites in the United States.Trial 1 and Trial 2 were used to evaluate the side effects of triheptanoin. Both trials enrolled children and adults diagnosed with LC-FAOD. In Trial 1, participants received triheptanoin for 78 weeks. Trial 2 enrolled participants from other trials who were already treated with triheptanoin (including those from Trial 1) as well as participants who were never treated with triheptanoin before. Trial 2 is still ongoing and is planned to last up to five years.The benefit of triheptanoin was evaluated in Trial 3 which enrolled children and adults with LC-FAOD. Half of the participants received triheptanoin and half received trioctanoin for four months. Neither the participants nor the investigators knew which treatment was given until the end of the trial. The benefit of triheptanoin in comparison to trioctanoin was assessed by measuring the changes in heart and muscle function. Names
Triheptanoin is the international nonproprietary name. References
Further reading
de Almeida Rabello Oliveira M, da Rocha Ataíde T, de Oliveira SL, de Melo Lucena AL, de Lira CE, Soares AA,  et al. (March 2008).
Fluorosis may refer to:

Dental fluorosis, a disturbance of dental enamel caused by excessive exposure to high concentrations of fluoride during tooth development. Skeletal fluorosis, a bone disease caused by excessive accumulation of fluoride in the bones
Fluoride toxicity, elevated levels of the fluoride ion in the body